Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma: A North Central Cancer Treatment Group Study, N0675

OBJECTIVE: Mammalian target of rapamycin (mTOR) pathway is activated in malignant melanoma and in situ lesions as opposed to benign nevi. Inhibition of PI3K-Akt-mTOR signaling is implicated in sensitization of melanoma cells to alkylating agents [temozolomide (TMZ)] and inhibition of tumor angiogene...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Clin Oncol
Hlavní autoři: Dronca, Roxana S., Allred, Jacob B., Perez, Domingo G., Nevala, Wendy K., Lieser, Elizabeth A.T., Thompson, Michael, Maples, William J., Creagan, Edward T., Pockaj, Barbara A., Kaur, Judith S., Moore, Timothy D., Marchello, Benjamin T., Markovic, Svetomir N.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4348017/
https://ncbi.nlm.nih.gov/pubmed/23357973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e31827b45d4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky